Medarex: ipilimumab decreases prostate specific antigen levels by 50%

By Elaine Rigoli

Tampa, Fla., June 5 - Medarex, Inc. released data from a two hormone refractory prostate cancer (HRPC) trials, including a phase 1 trial of ipilimumab in combination with GM-CSF (sargramostim) and a phase 2 trial of ipilimumab alone or in combination with chemotherapy.

In the first clinical trial to combine ipilimumab and GM-CSF, a cytokine that stimulates the proliferation of white blood cells and augments immune responses, two of three patients with HRPC treated at the highest dose of ipilimumab (3.0 mg/kg) experienced confirmed decreases in prostate specific antigen (PSA) serum levels of greater than 50%, according to a news release.

In a phase 2 clinical trial of ipilimumab alone or in combination with docetaxel, three of the 24 patients with HRPC treated with ipilimumab alone experienced decreases in PSA serum levels of more than 50%, with one confirmed response of 246 days in duration, one confirmed response of at least 79 days and one unconfirmed response.

Three of the 20 patients treated with ipilimumab in combination with docetaxel experienced decreases in PSA serum levels of more than 50%, with one confirmed response of 280 days in duration and two unconfirmed responses, the release said.

Medarex is a biopharmaceutical company located in Princeton, N.J.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.